Pharmacokinetics, safety and transplacental passage of rilpivirine in pregnancy: Two cases

AIDS

Volumn 28, Issue 2, 2014, Pages 288-290

  Colbers, Angela ^a   Gingelmaier, Andrea ^b   Van Der Ende, Marchina ^c   Rijnders, Bart ^c   Burger, David ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF MUNICH   (Germany)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ATAZANAVIR PLUS RITONAVIR; EMTRICITABINE PLUS RILPIVIRINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; NICOTINE; RILPIVIRINE;

ADULT; ALCOHOL CONSUMPTION; ALCOHOLISM; APGAR SCORE; AREA UNDER THE CURVE; CASE REPORT; CESAREAN SECTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FETOMATERNAL TRANSFUSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MATERNAL BLOOD; MAXIMUM PLASMA CONCENTRATION; PHARMACOLOGICAL PARAMETERS; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PUERPERIUM; SMOKING; TOBACCO DEPENDENCE; UMBILICAL CORD BLOOD; VIRUS LOAD; YOUNG ADULT;

ANTI-HIV AGENTS; FEMALE; FETAL BLOOD; HIV INFECTIONS; HUMANS; NITRILES; PLASMA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PYRIMIDINES; YOUNG ADULT;

EID: 84892186163     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000100     Document Type: Letter

References (5)

1. DHHS. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. 31 July 2012. pp. 1-235. http://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf 2012. [Accessed 15 April 2013]
2. EMA. Eviplera; summary of product characteristics. http://www. ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002312/ WC500118802.pdf 2013. [Accessed 26 August 2013]
3. Colbers AP, Hawkins DA, Gingelmaier A, Kabeya K, Rockstroh JK, Wyen C, et al. The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women. AIDS 2013; 27:739-748.
4. Crauwels H, Van Schaick E, Van Heeswijk R, Vanveggel S, Boven K, Vis P. Effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral naive, HIV-1-infected patients in ECHO and THRIVE. J Int AIDS Soc 2010; 13 (Suppl 4):P186.
5. FDA. Edurant, clinical pharmacology review. http://www. accessdata.fda.gov/drugsatfda-docs/nda/2011/202022Orig1s000 ClinPharmR.pdf 2011. [Accessed 04 September 2013]